Menu
We recently presented two posters at the European Congress of Pathology 2024, in Florence, Italy, in collaboration with Janssen Pharmaceutical, a Johnson & Johnson company.
The posters provided real-world data insights on the genomic landscape of specific biomarkers associated with lung and prostate cancers, in a subset of European countries.
The first poster spotlight features Stefano Cheloni, Senior Bioinformatician - Tertiary Analysis at SOPHiA GENETICS, presenting the poster titled: “Real-world insights from France, Italy, Spain, and Austria for the investigation of common (exons 19,21) and rare (exons 18, 20) EGFR mutations in lung cancer”.
The identification of exon-specific EGFR mutations can guide the appropriate treatment of lung cancer with tyrosine kinase inhibitors (TKIs) or alternative targeted therapies. This project aimed to explore the landscape of next-generation sequencing (NGS) testing practices for EGFR mutations in clinical practice in a subset of European countries, to determine the potential number of individuals with lung cancer that could benefit from treatment with TKIs or alternative targeted therapies.
Read the EGFR poster through here.
Watch the spotlight below:
In our second poster spotlight, Adrian Janiszewski, Manager Bioinformatician - Team Lead Tertiary Analysis at SOPHiA GENETICS, showcases a poster titled: “NGS testing practices and molecular profiles of BRCA1/2 in prostate cancer: Real-world insights from France, Italy, Spain, and Austria”.
BRCA1/2 testing can inform which prostate cancer patients might respond to PARP inhibitors (PARPi). Having a better understanding of BRCA1/2 testing practices in the real-world setting can provide valuable insights into identifying gaps and opportunities to improve the identification of metastatic prostate cancer (mPC) patients who may benefit from PARPi treatment. In this study we investigated NGS testing practices results across specific European countries.
Read the BRCA 1 & 2 poster through here.
Watch the spotlight below:
We would like to warmly thank Stefano and Adrian for their insightful presentations and for sharing the key takeaways of these projects.
Learn more about SOPHiA DDM™ for BioPharma, by visiting the page.
DISCLAIMER:
All product and company names are trademarks™ or registered trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
